Physician profile
Stacy E Simons
NPI 1952844185
$4,251.55
in general payments reported to CMS, 2019-2025
37 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $196 · 2023: $469 · 2024: $1,110 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,747 · Education: $102 · Travel and Lodging: $8.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,746.90 |
| Education | $102.36 |
| Travel and Lodging | $8.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.62 | 2021-2025 | |
| Lilly USA, LLC | $485.85 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $321.57 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Ucb, INC. | $308.30 | 2023-2025 | Zilbrysq, Briviact |
| Neurocrine Biosciences, INC. | $234.63 | 2025 | |
| Pfizer INC. | $191.53 | 2021-2025 | |
| Sk Life Science, INC. | $174.04 | 2025 | |
| Neurelis, INC. | $115.88 | 2024-2025 | Valtoco |
| Incyte Corporation | $115.64 | 2024 | Opzelura |
| Otsuka America Pharmaceutical, INC. | $103.16 | 2025 | Rexulti |
| Medtronic, INC. | $102.36 | 2025 | Percept PC Brainsense |
| Corium, LLC | $87.75 | 2022-2023 | Adlarity |
| Argenx US, INC. | $77.60 | 2022-2025 | Vyvgart Hytrulo |
| Genentech USA, INC. | $68.21 | 2022-2025 | Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $64.61 | 2024-2025 | Crexont |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $61.39 | 2023-2024 | Fycompa |
| Grifols USA, LLC | $60.38 | 2023-2025 | Gamunex-C |
| Eisai INC. | $59.50 | 2022-2024 | |
| Axsome Therapeutics, INC. | $53.61 | 2025 | Symbravo |
| Biogen, INC. | $51.89 | 2025 | Leqembi |
| Lundbeck LLC | $49.76 | 2023-2025 | Vyepti |
| Glaxosmithkline, LLC. | $43.33 | 2021-2023 | Shingrix, Arexvy |
| Tersera Therapeutics LLC | $36.90 | 2025 | Quzyttir |
| Mdd US Operations, LLC | $35.07 | 2025 | Apokyn |
| Alnylam Pharmaceuticals INC. | $32.28 | 2024 | Amvuttra |
| Tonix Medicines, INC. | $32.10 | 2025 | Zembrace Symtouch |
| Merz Pharmaceuticals, LLC | $28.35 | 2024 | Xeomin |
| Alexion Pharmaceuticals, INC. | $25.61 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $24.22 | 2021 | |
| Csl Behring | $24.19 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.54 | 2025 | Dysport |
| Biohaven Pharmaceutical Holding Company LTD. | $22.95 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.07 | 2023 | Ztlido |
| Impel Pharmaceuticals LLC | $18.53 | 2024 | Trudhesa |
| Novo Nordisk INC | $17.39 | 2024 | Ozempic |
| Kyowa Kirin, INC. | $16.93 | 2024 | Nourianz |
| Chiesi USA, INC. | $16.81 | 2023 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.